tetano
Editor, Senior Moderator
Nat Metab
. 2021 May 25.
doi: 10.1038/s42255-021-00407-6. Online ahead of print.
Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection
Laura Montefusco[SUP] #[/SUP][SUP] 1 [/SUP], Moufida Ben Nasr[SUP] #[/SUP][SUP] 2 3 [/SUP], Francesca D'Addio[SUP] #[/SUP][SUP] 2 [/SUP], Cristian Loretelli[SUP] 2 [/SUP], Antonio Rossi[SUP] 1 [/SUP], Ida Pastore[SUP] 1 [/SUP], Giuseppe Daniele[SUP] 4 [/SUP], Ahmed Abdelsalam[SUP] 2 [/SUP], Anna Maestroni[SUP] 2 [/SUP], Marco Dell'Acqua[SUP] 2 5 [/SUP], Elio Ippolito[SUP] 2 [/SUP], Emma Assi[SUP] 2 [/SUP], Vera Usuelli[SUP] 2 [/SUP], Andy Joe Seelam[SUP] 2 [/SUP], Roberta Maria Fiorina[SUP] 2 [/SUP], Enrica Chebat[SUP] 1 [/SUP], Paola Morpurgo[SUP] 1 [/SUP], Maria Elena Lunati[SUP] 1 [/SUP], Andrea Mario Bolla[SUP] 1 [/SUP], Giovanna Finzi[SUP] 6 [/SUP], Reza Abdi[SUP] 7 [/SUP], Joseph V Bonventre[SUP] 7 [/SUP], Stefano Rusconi[SUP] 8 [/SUP], Agostino Riva[SUP] 8 [/SUP], Domenico Corradi[SUP] 9 [/SUP], Pierachille Santus[SUP] 10 11 [/SUP], Manuela Nebuloni[SUP] 12 13 [/SUP], Franco Folli[SUP] 14 [/SUP], Gian Vincenzo Zuccotti[SUP] 1 15 [/SUP], Massimo Galli[SUP] 8 [/SUP], Paolo Fiorina[SUP] 16 17 18 [/SUP]
Affiliations
Abstract
Patients with coronavirus disease 2019 (COVID-19) are reported to have a greater prevalence of hyperglycaemia. Cytokine release as a consequence of severe acute respiratory syndrome coronavirus 2 infection may precipitate the onset of metabolic alterations by affecting glucose homeostasis. Here we describe abnormalities in glycometabolic control, insulin resistance and beta cell function in patients with COVID-19 without any pre-existing history or diagnosis of diabetes, and document glycaemic abnormalities in recovered patients 2 months after onset of disease. In a cohort of 551 patients hospitalized for COVID-19 in Italy, we found that 46% of patients were hyperglycaemic, whereas 27% were normoglycaemic. Using clinical assays and continuous glucose monitoring in a subset of patients, we detected altered glycometabolic control, with insulin resistance and an abnormal cytokine profile, even in normoglycaemic patients. Glycaemic abnormalities can be detected for at least 2 months in patients who recovered from COVID-19. Our data demonstrate that COVID-19 is associated with aberrant glycometabolic control, which can persist even after recovery, suggesting that further investigation of metabolic abnormalities in the context of long COVID is warranted.
. 2021 May 25.
doi: 10.1038/s42255-021-00407-6. Online ahead of print.
Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection
Laura Montefusco[SUP] #[/SUP][SUP] 1 [/SUP], Moufida Ben Nasr[SUP] #[/SUP][SUP] 2 3 [/SUP], Francesca D'Addio[SUP] #[/SUP][SUP] 2 [/SUP], Cristian Loretelli[SUP] 2 [/SUP], Antonio Rossi[SUP] 1 [/SUP], Ida Pastore[SUP] 1 [/SUP], Giuseppe Daniele[SUP] 4 [/SUP], Ahmed Abdelsalam[SUP] 2 [/SUP], Anna Maestroni[SUP] 2 [/SUP], Marco Dell'Acqua[SUP] 2 5 [/SUP], Elio Ippolito[SUP] 2 [/SUP], Emma Assi[SUP] 2 [/SUP], Vera Usuelli[SUP] 2 [/SUP], Andy Joe Seelam[SUP] 2 [/SUP], Roberta Maria Fiorina[SUP] 2 [/SUP], Enrica Chebat[SUP] 1 [/SUP], Paola Morpurgo[SUP] 1 [/SUP], Maria Elena Lunati[SUP] 1 [/SUP], Andrea Mario Bolla[SUP] 1 [/SUP], Giovanna Finzi[SUP] 6 [/SUP], Reza Abdi[SUP] 7 [/SUP], Joseph V Bonventre[SUP] 7 [/SUP], Stefano Rusconi[SUP] 8 [/SUP], Agostino Riva[SUP] 8 [/SUP], Domenico Corradi[SUP] 9 [/SUP], Pierachille Santus[SUP] 10 11 [/SUP], Manuela Nebuloni[SUP] 12 13 [/SUP], Franco Folli[SUP] 14 [/SUP], Gian Vincenzo Zuccotti[SUP] 1 15 [/SUP], Massimo Galli[SUP] 8 [/SUP], Paolo Fiorina[SUP] 16 17 18 [/SUP]
Affiliations
- PMID: 34035524
- DOI: 10.1038/s42255-021-00407-6
Abstract
Patients with coronavirus disease 2019 (COVID-19) are reported to have a greater prevalence of hyperglycaemia. Cytokine release as a consequence of severe acute respiratory syndrome coronavirus 2 infection may precipitate the onset of metabolic alterations by affecting glucose homeostasis. Here we describe abnormalities in glycometabolic control, insulin resistance and beta cell function in patients with COVID-19 without any pre-existing history or diagnosis of diabetes, and document glycaemic abnormalities in recovered patients 2 months after onset of disease. In a cohort of 551 patients hospitalized for COVID-19 in Italy, we found that 46% of patients were hyperglycaemic, whereas 27% were normoglycaemic. Using clinical assays and continuous glucose monitoring in a subset of patients, we detected altered glycometabolic control, with insulin resistance and an abnormal cytokine profile, even in normoglycaemic patients. Glycaemic abnormalities can be detected for at least 2 months in patients who recovered from COVID-19. Our data demonstrate that COVID-19 is associated with aberrant glycometabolic control, which can persist even after recovery, suggesting that further investigation of metabolic abnormalities in the context of long COVID is warranted.